European Committee for Treatment and Research in Multiple Sclerosis Congress
Neurology - 06 Nov 2018
AAT-ADPD 2018 oral presentation- Analysis of factors and methodologic considerations affecting plaque reduction measures via PET in the gantenerumab open-label extension studies
Gantenerumab is a fully human monoclonal antibody currently under evaluation at titrated doses up to 1200 mg sc monthly in the Scarlet RoAD (SR, NCT01224106) and Marguerite RoAD (MR, NCT02051608) open label extension (OLE) studies. High levels of florbetapir PET amyloid reduction in Alzheimer’s patients has been observed with gantenerumab treatment, measured by standard uptake value ratio (SUVR) methods using a cerebellar grey reference region. Here we report amyloid burden using alternative SUVR methods (template-space and native-space Freesurfer), and relate amyloid reductions to factors including baseline SUVR and dosing schedules.
Oncology - 05 Nov 2018
EBCC 2018 poster: Adjuvant pertuzumab for HER2-positive early stage breast cancer: a Swiss experience
In Switzerland, physicians can treat patients with unlicensed adjuvant pertuzumab through a special access mechanism by Swiss law (KVV71 a/b). This poster describes the experience of 12 patients treated with adjuvant pertuzumab, before the publication of APHINITY trial’s results, in the real-world setting in Switzerland. Patients treated with adjuvant pertuzumab between July 2015 and March 2017 at three Swiss cancer centers were identified.
Oncology - 29 Oct 2018
ASCO-GU 2018 oral - IMmotion151: A Randomized Phase III Study of ▼Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma
IMmotion151 is randomized Phase III study evaluating the efficacy and safety ▼atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib in patients with treatment-naive advanced or metastatic renal cell carcinoma (RCC). Coprimary endpoints were investigator-assessed progression-free survival (PFS) in PD-L1 + (≥ 1% PD-L1 expression on tumor-infiltrating immune cells) patients and overall survival (OS) in intent-to-treat (ITT) patients; secondary endpoints included PFS in ITT patients, ORR and DOR.